Skip to content

Comparison of Katakakhadiradi kashay Ghan vati and oral Hypoglycemic drug in Prameha(Diabetes mallitus).

A Randomized Standard Controlled Clinical trial to evaluate an add on effect of Katakakhadiradi kashay Ghan vati with oral Hypoglycemic drug in Prameha

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047595
Enrollment
56
Registered
2022-11-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

PDEAs College of Ayurved and Research Centre Sector no.-25, Nigdi, Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Sign and symptoms of Prameha 2.known case of Type-2 DM, NIDDM 3.Patient having HbA1C upto-10 4.Fasting blood sugar upto 250 mg% and post prandial blood sugar upto 350 mg% 5.patient taking Metformin+Glimepride drug since min 6 months

Exclusion criteria

Exclusion criteria: 1.Juvenile Diabetes and Insulin Dependent Diabetes Mellitus (IDDM). 2.Patients with CKD and AKD. 3.Patients with acute complications Hyperglycemic & hypoglycemic coma,Ketoacidosis and related complication and Infections like gangrene. 4.Patients with chronic diabetic complications Nephropathy, Neuropathy and Retinopathy. 5.Pregnant & lactating women. 6.Patients suffering from all major systemic diseases IHD, TB, CA.

Design outcomes

Primary

MeasureTime frame
To evaluate an efficacy of katakakhadiradi Ghan Vati 500mg twice a day before meal with koshnajala for 3 months as an add on effect to oral hypoglycemic agent in Prameha.Timepoint: 90 days with follow up on 15th,30th,45th,60th,75th,90th day

Secondary

MeasureTime frame
1.To compare and study the efficacy of Katakakhadiradi Ghan Vati for 3 months. 2.To compare and study the efficacy of oral hypoglycemic agent for 3 months. 2.To study the adverse effect if anyTimepoint: 90 days with follow up on 15th,30th,45th,60th,75th,90th day

Countries

India

Contacts

Public ContactDr Tejal Kiran Suryawanshi

PDEAs College Of Ayurved and Research Centre, Nigdi, Pune

medhamaheshjoshi@gmail.com9881465798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026